Table 4.

Simulated power (%)^a results for the FLU-IVIG placebo group on day 7 of follow-up ($p_{07}$^b  = 0.63).^c

Model	T1: Constant benefitd	T2: Benefit only for first three days	T3: Linear decrease in benefit	T4: Larger benefit for hospitalized patients	T5: Benefit only for ICU and non-ICU, on oxygen patients	T6: Benefit only for last three days	T7: Linear increase in benefit
No adjustment for baseline status
Simple Logistic	71.65	75.07	75.29	76.70	83.20	60.79	67.87
Sliding Dichotomy	69.55	78.04	75.71	74.81	93.04	59.11	64.11
Win Ratio	79.54	79.58	79.38	79.61	79.66	79.86	80.66
Proportional Odds	79.71	79.69	79.45	79.68	79.86	79.94	80.77
Longitudinal Ordinal Outcome	82.98	71.52	77.96	83.35	67.21	79.45	84.59
Cox Proportional Hazards	76.73	96.46	92.66	81.92	87.47	36.39	53.81
Accelerated Failure Time (Exponential)	68.43	94.24	89.17	74.72	81.44	27.45	42.49
Accelerated Failure Time (Weibull)	78.83	96.64	93.62	83.78	88.55	37.09	55.83
Adjustment for baseline status
Simple Logistic	78.70	81.24	82.28	83.68	86.08	68.84	75.55
Sliding Dichotomy	71.96	79.82	77.92	77.49	93.29	61.88	67.09
Win Ratioe	83.67	82.90	82.59	83.94	72.09	86.26	86.14
Proportional Odds	86.25	86.50	85.95	86.50	87.26	86.93	86.70
Longitudinal Ordinal Outcome	70.45	23.81	42.36	70.12	53.20	84.90	85.63
Cox Proportional Hazards	84.93	98.92	96.89	89.27	81.81	40.94	60.28
Accelerated Failure Time (Exponential)	74.41	97.37	93.94	80.50	75.69	26.67	43.51
Accelerated Failure Time (Weibull)	86.23	98.98	97.21	90.48	82.51	41.08	61.99

^aPower (%): percentage of the 10,000 simulated datasets in which the Wald test statistic for the estimated treatment effect of the fitted model was significant at the two-sided 0.05 level. Power for the top three models for each treatment effect with or without adjustment for baseline health status is printed in bold.

^b$p_{07}$ denotes the probability of discharge (i.e., categories 5 and 6 of the ordinal endpoint combined) by day 7 of follow-up for the placebo group.

^cSupplementary Table 1 displays the category percentages for the FLU-IVIG placebo group on day 7 and each of the seven IVIG groups.

^dBenefit refers to the differences in transition probabilities between randomized groups across treatment effects.

^eUnlike all other models which include a covariate to adjust for baseline status, the win ratio stratifies by only comparing patients who started at the same baseline category between randomized groups.